Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F10 | P00742 | 2/20 | 0.41 |
| ▸ | ACKR3 | P25106 | 6/20 | 0.37 |
| ▸ | NOS1 | P29475 | 2/20 | 0.35 |
| ▸ | NOS3 | P29474 | 1/20 | 0.35 |
| ▸ | NQO2 | P16083 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | PTAFR | P25105 | 2/20 | 0.34 |
| ▸ | PRSS1 | P07477 | 1/20 | 0.34 |
| ▸ | FAAH | O00519 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16603473 | 0.95 | F10 (0.38) | F10ACKR3NOS1NOS3NQO2 | |
| SCHEMBL16603474 | 0.93 | IKBKB (0.36) | F10ACKR3NOS1NOS3NQO2 | |
| SCHEMBL15244944 | 0.92 | F10 (0.46) | F10NOS1NOS3POLBPTAFR | |
| SCHEMBL16603461 | 0.86 | F10 (0.42) | F10NOS1NOS3POLBPTAFR | |
| SCHEMBL15245043 | 0.84 | NOS1 (0.38) | NOS1NOS3 | |
| SCHEMBL16605480 | 0.84 | CDK8 (0.39) | F10NOS1NOS3CYP11B2 | |
| SCHEMBL16603492 | 0.83 | PRSS1 (0.39) | F10PRSS1 | |
| SCHEMBL16605481 | 0.82 | MKNK1 (0.41) | F10NOS1NOS3PTAFRPRSS1 | |
| SCHEMBL16603484 | 0.81 | F10 (0.38) | F10NOS1NOS3PTAFRCYP11B2 | |
| SCHEMBL15244879 | 0.80 | CYP2A6 (0.43) | NOS1NOS3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150094294-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2015-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150094294-A1 | COMPOUNDS AND METHODS FOR TREATING MALARIA | PC, CPS1, GLS2 | F10 3742/4885ACKR3 2190/4885NOS1 2056/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.